Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study
Abstract
Aim: Head-to-head clinical trials of teriflunomide (TFM) versus dimethyl fumarate (DMF) have not been conducted. Objectives: To compare the real-world effectiveness of TFM versus DMF. Methods: Anonymized data were collected from patients with relapsing multiple sclerosis (MS) initiating treatment with teriflunomide (N = 50) or DMF (N = 50). Results: On follow-up magnetic resonance imaging (MRI) compared with baseline, with TFM versus DMF treatment, the proportion of patients with new/enlarging T2 or gadolinium-enhancing lesions was 30.0 versus 40.0% (p = 0.2752). However, median annualized percent whole brain volume change was -0.1 versus -0.5 (p = 0.0212). There were no significant treatment differences on additional MRI and clinical end points and no unexpected safety signals. Conclusion: The effectiveness of teriflunomide was superior to DMF on whole brain atrophy and similar to DMF on other MRI/clinical end points.
Supplementary Material
File (supplementary_materials.docx)
- Download
- 27.31 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol. Scand. 124, 75–84 (2011).
2.
Confavreux C, O'Connor P, Comi G et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet Neurol. 13, 247–256 (2014).
3.
O'Connor P, Wolinsky JS, Confavreux C et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 365, 1293–1303 (2011).
4.
Radue EW, Sprenger T, Gaetano L et al. Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA. Neurol. Neuroimmunol. Neuroinflamm. 4, e390 (2017).
5.
Linker RA, Gold R. Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects. Curr. Neurol. Neurosci. Rep 13, 394 (2013).
6.
Fox RJ, Miller DH, Phillips JT et al. Placebo-controlled Phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 367, 1087–1097 (2012).
7.
Gold R, Kappos L, Arnold DL et al. Placebo-controlled Phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 367, 1098–1107 (2012).
8.
Zivadinov R, Khan N, Medin J et al. An observational study to assess brain MRI change and disease progression in multiple sclerosis clinical practice – the MS-MRIUS study. J. Neuroimaging 27, 339–347 (2017).
9.
Zivadinov R, Bergsland N, Korn JR et al. Feasibility of brain atrophy measurement in clinical routine without prior standardization of the MRI protocol: results from MS-MRIUS, a longitudinal observational, multicenter real-world outcome study in patients with relapsing-remitting MS. AJNR Am. J. Neuroradiol. 39, 289–295 (2018).
• Demonstrates feasibility of retrospectively assessing longitudinal brain magnetic resonance imaging changes in routine clinical practice.
10.
Weinstock-Guttman B, Medin J, Khan N et al. Assessing ‘no evidence of disease activity’ status in patients with relapsing-remitting multiple sclerosis receiving fingolimod in routine clinical practice: a retrospective analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) study. CNS Drugs 32, 75–84 (2018).
11.
Zivadinov R, Havrdova E, Bergsland N et al. Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology 268, 831–841 (2013).
12.
Zivadinov R, Dwyer M, Barkay H, Steinerman JR, Knappertz V, Khan O. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense “black holes”: a post hoc magnetic resonance imaging analysis. J. Neurol. 262, 648–653 (2015).
13.
Smith SM, Zhang Y, Jenkinson M et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17, 479–489 (2002).
• Describes method used to measure longitudinal change in whole brain volume from images acquired at different time points.
14.
Dwyer MG, Silva D, Bergsland N et al. Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical- quality T2-FLAIR MRI scans in multiple sclerosis. Neuroimage Clin. 15, 769–779 (2017).
• Demonstrates that measurement of lateral ventricle volume changes relates to clinical outcomes.
15.
De Stefanox N, Stromillo ML, Giorgio A et al. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 87, 93–99 (2016).
•• Provides evidence-based cut-off for pathological brain atrophy rate in multiple sclerosis (MS) (% brain volume change per year of -0.4%) and demonstrates clinical relevance.
16.
Dwyer MG, Hagemeier J, Bergsland N et al. Establishing pathological cut-offs for lateral ventricular volume expansion rates. Neuroimage Clin. 18, 494–501 (2018).
•• Provides evidence-based cut-off for pathological lateral ventricular volume expansion rate in MS (% lateral ventricular volume change per year of 3.5%) and demonstrates clinical relevance.
17.
Freedman MS, Montalban X, Miller AE et al. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis. Mult. Scler. Relat. Disord. 10, 204–212 (2016).
18.
Freedman MS, Hughes B, Mikol DD et al. Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison. Eur. Neurol. 60, 1–11 (2008).
19.
Miller AE, Wolinsky JS, Kappos L et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet Neurol. 13, 977–986 (2014).
20.
Popescu V, Agosta F, Hulst HE et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 84, 1082–1091 (2013).
21.
Zivadinov R, Khan N, Korn JR et al. No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the Multiple Sclerosis, Clinical, and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) study. Curr. Med. Res. Opin. 34, 1431–1440 (2018).
22.
Zivadinov R, Medin J, Khan N et al. Fingolimod's impact on MRI brain volume measures in multiple sclerosis: results from MS-MRIUS. J. Neuroimaging 28, 399–405 (2018).
23.
Zivadinov R, Medin J, Khan N et al. Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: a retrospective analysis of the Multiple Sclerosis, Clinical and MRI Outcomes in the USA (MS-MRIUS) study. Mult. Scler. Relat. Disord. 27, 65–73 (2018).
24.
Weinstock-Guttman B, Medin J, Khan N et al. Assessing ‘no evidence of disease activity’ status in patients with relapsing-remitting multiple sclerosis receiving fingolimod in routine clinical practice: a retrospective analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging in the USA (MS-MRIUS) Study. CNS Drugs 32, 75–84 (2018).
25.
Zivadinov R, Reder AT, Filippi M et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 71, 136–144 (2008).
Information & Authors
Information
Published In
Copyright
© 2019 Stanley Cohan.
History
Received: 28 November 2018
Accepted: 10 January 2019
Published online: 13 February 2019
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study. (2019) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2018-0135
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Nicole Vasilenko, Maria P. Tieck, Tanja Michel, Sonja Schembecker, Patricia Schwarz, Anna Guenther, Christoph Ruschil, Sven Poli, Ulf Ziemann, Antje Giede-Jeppe, Gisela Gabernet, Alex Dulovic, Markus C. Kowarik, In-depth analysis of serum antibodies against Epstein-Barr virus lifecycle proteins, and EBNA1, ANO2, GlialCAM and CRYAB peptides in patients with multiple sclerosis, Frontiers in Immunology, 10.3389/fimmu.2024.1487523, 15, (2024).
- Rui Li, Jing Zhou, Haotian Wu, Yuge Wang, Juanjuan Chen, Sustained Effectiveness and Safety Over Time of Teriflunomide in Chinese Patients with Relapsing Multiple Sclerosis in the Greater Bay Area of China: Insights from Real-World Data, Neurology and Therapy, 10.1007/s40120-024-00599-5, 13, 4, (1117-1133), (2024).
- Stefan Verweij, Wouter Ahmed, Guiling Zhou, Dimitris Mavridis, Stavros Nikolakopoulos, Andre J. Elferink, Katrien Oude Rengerink, Maarten J. Bijlsma, Peter G. M. Mol, Eelko Hak, Do efficacy results obtained from randomized controlled trials translate to effectiveness data from observational studies for relapsing–remitting multiple sclerosis?, Pharmacoepidemiology and Drug Safety, 10.1002/pds.5810, 33, 5, (2024).
- Hongmei Tan, Xiang Li, Yuxin Li, Fanru He, Jingzi ZhangBao, Lei Zhou, Liqin Yang, Chongbo Zhao, Chuanzhen Lu, Qiang Dong, Haiqing Li, Chao Quan, Real-world experience of teriflunomide in relapsing multiple sclerosis: paramagnetic rim lesions may play a role, Frontiers in Immunology, 10.3389/fimmu.2024.1343531, 15, (2024).
- Luca Prosperini, Shalom Haggiag, Serena Ruggieri, Carla Tortorella, Claudio Gasperini, Dimethyl Fumarate or Teriflunomide for Relapsing–Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing Studies, Neurotherapeutics, 10.1007/s13311-023-01416-x, 20, 5, (1275-1283), (2023).
- Damiano Marastoni, Francesco Crescenzo, Anna I Pisani, Carmela Zuco, Gianmarco Schiavi, Giulia Benedetti, Giuseppe K Ricciardi, Stefania Montemezzi, Francesca B Pizzini, Agnese Tamanti, Massimiliano Calabrese, Two years’ effect of dimethyl fumarate on focal and diffuse gray matter pathology in multiple sclerosis, Multiple Sclerosis Journal, 10.1177/13524585221104014, 28, 13, (2090-2098), (2022).
- Yao Zhang, Hexiang Yin, Dingding Zhang, Yan Xu, Bin Peng, Liying Cui, Real-world outcomes of teriflunomide in relapsing–remitting multiple sclerosis: a prospective cohort study, Journal of Neurology, 10.1007/s00415-022-11118-7, 269, 9, (4808-4816), (2022).
- Aaron E Miller, An Updated Review of teriflunomide’s Use in Multiple Sclerosis, Neurodegenerative Disease Management, 10.2217/nmt-2021-0014, 11, 5, (387-409), (2021).
- Viktoria Papp, Mathias Due Buron, Volkert Siersma, Peter Vestergaard Rasmussen, Zsolt Illes, Matthias Kant, Claudia Hilt, Zsolt Mezei, Homayoun Roshanisefat, Tobias Sejbæk, Arkadiusz Weglewski, Janneke van Wingerden, Svend Sparre Geertsen, Stephan Bramow, Finn Sellebjerg, Melinda Magyari, Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry, PLOS ONE, 10.1371/journal.pone.0250820, 16, 5, (e0250820), (2021).
- Robert Zivadinov, Michael G. Dwyer, Ellen Carl, Elizabeth M. Poole, Steve Cavalier, Paraskevi Briassouli, Niels Bergsland, Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS, Therapeutic Advances in Neurological Disorders, 10.1177/1756286420970754, 13, (2020).